中信建投研報稱,在政策上,集採與醫保談判常態化,商保帶來潛在增量,對創新藥的支持力度有望進一步增加。在技術上,全球ADC藥物2023年銷售額達104億美元,中國相關公司加速ADC佈局與推進,逐漸迎來收穫期;GLP-1減重賽道發展成熟,競爭從單一減重升級到多重獲益,新靶點存在潛在出海機會;IO多抗賽道AK112率先實現突破,TCE技術從血液瘤走向實體瘤和自免。
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Amid the turbulence in the Global market due to tariffs, understand Trump's 11 Trade principles in one article.
Essential for US stock investment! Key events in April can be previewed, and the days that influence price fluctuations have all been marked.
Not ruling out a third term for the president of the USA? Trump: I'm not joking.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
中信建投:持续看好创新药行业
中信建投:持續看好創新藥行業
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 405
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report